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Abstract Discordant data are reported in the literature on the
definition, incidence and clinical features of neuroendocrine
(NE) carcinomas of the breast. This tumour entity is currently
assessed by immunohistochemistry (IHC) detecting “general”
NE markers such as chromogranin A (CHGA) and
synaptophysin (SYP), but other markers have been considered
as well. In the present study, in addition to CHGA and SYP,
we investigated the expression of VGF, a neurotrophin-
inducible gene, which is emerging as a new specific NE
marker. In order to evaluate the differential expression of these
neuro-endocrine markers in breast cancers, we conducted
parallel immunohistochemical and gene expression analyses,
using PCR, gene array and real-time quantitative PCR proce-
dures. Data obtained in 28 cases were further validated with a
meta-analysis of published datasets of 103 breast cancer cases.
The value of IHC positivity (irrespective of the percentage of
positive cells) was confirmed by over-expression of the relat-
ed gene. However, the genetic approach emerged as more
sensitive, showing over-expression of NE markers in a subset
of IHC-negative carcinomas. In conclusion, the present study
confirms, by a novel approach, the occurrence of NE differen-
tiation in breast cancers. Over-expression of one or more NE
marker (CHGA and/or SYP and/or VGF) characterizes a signif-
icant fraction (approximately 10%) of infiltrative breast cancers.
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Introduction
The reported incidence of neuroendocrine (NE) differentiation
in invasive breast carcinomas (IBC) is variable from 2 up to
20 %, depending on the criteria and detection methods [1–3].
On the basis of morphological and immunohistochemical fea-
tures, the 2003 World Health Organization (WHO) Classifica-
tion of Tumors of the Breast defined neuroendocrine carcinoma
(NEC) of the breast as a rare subtype of invasive mammary
carcinoma showing: (1) presence of morphologic features sim-
ilar to those of NE tumours of the gastrointestinal tract and lung,
and (2) expression of NE markers (chromogranin A and/or
synaptophysin) in more than 50 % of tumour cells [3, 4]. The
WHO estimated these uncommon tumours as representing
approximately 2 % of all breast carcinomas. Cases of IBC with
scanty positive cells did not fall into this definition.
In the 2012 revised WHO classification, the NEC defini-
tion included three categories: (1) NEC, well-differentiated
(carcinoid-like pattern), (2) NEC, poorly differentiated/small
cell carcinoma and (3) IBC with NE differentiation deter-
mined by immunohistochemistry (IHC) [5]. All of these tu-
mours should express NE markers to a greater or a lesser
degree and in this WHO classification the minimum quantity
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of tumour cells expressing NE markers for defining an IBC as
NEC was not specified.
Currently, NE differentiation in breast cancers has been
assessed by immunohistochemical procedures detecting “gen-
eral” NE markers such as chromogranin A (CHGA) and
synaptophysin (SYP), and elucidation of specific hormonal
peptides has been absent or unproductive [6]. Recently, we
have shown the human achaete-scute homolog-1 (hASH-1), a
transcription factor that plays a key role in the regulation of
mammalian neural and NE cell development, is expressed in
NE breast tumours [7].
In the present study, in addition to CHGA and SYP, we
investigate the expression of VGF, a neurotrophin-inducible
gene, which is emerging as a new specific marker of NE
differentiation [8]. The VGF (not acronymic) gene was origi-
nally detected on the basis of its regulation by nerve growth
factor in rat pheochromocytoma PC12 cells [9] and by brain-
derived neutrophic factor and neurotrophin 3 in cultures of
neurons [10]. The coded polypeptide of 615 amino acids has
a predicted molecular weight of 67 kDa and shares similarities
with members of the secretogranin/chromogranin family [11].
This peptide is detectable in subsets of neurons and was found
to regulate the hypothalamus–hypophysis–gonad axis [12].
Additionally, VGF peptides have been detected in several types
of NE cells within the diffuse neuroendocrine system [13].
In order to evaluate the differential expression of salient
neuro-endocrine markers in breast cancers, we conducted paral-
lel immunohistochemical and gene expression analyses in a
series of breast cancers. The results indicate that the latter
approach is more sensitive and that expression of at least one
NEmarker in breast cancer is a relatively frequent phenomenon.
Materials and Methods
Cases
Twenty-eight invasive breast carcinomas were analysed. A
tissue sample (4 mm thick) was fixed in 4 % neutral-
buffered formalin (Histo-Line Laboratories, Milan, Italy) at
room temperature and embedded in formalin by routine pro-
cessing (FFPE). In four cases (cases 1–4) one parallel sample
(4 mm thick) was embedded in Tissue-Tek® OCT™ Com-
pound, snap frozen in isopentane immediately after dissection
and stored at −80 °C. For 24 out of the 28 cases (cases 5–28),
Trizol-preserved leftovers from the pre-operative fine-needle
aspiration biopsies (FNAB) were also available for gene ex-
pression analysis, as recently described [14].
According to the recently updated WHO classification
[15], cases were classified as follows: 19 invasive carcinomas
not special type (IC-NST), one medullary carcinoma, one
infiltrating lobular carcinoma, one tubular carcinoma, two
intracystic papillary carcinomas and four cases that fulfilled
the 2003 WHO definition of NE carcinomas of the breast by
positivity by immunohistochemistry for CHGA and/or SYP
in>50 % of cancer cells. Non-neoplastic breast tissue samples
obtained from two mastectomies were processed with the
same protocol for breast cancer specimens and were used as
negative controls.
In addition, we also retrieved two cases of pheochromocy-
toma of the adrenal gland (fixed and frozen samples), which
were used as positive controls.
Immunohistochemistry
Immunohistochemistry was performed on FFPE tissue sec-
tions from each case using an automated slide processing
platform (Ventana BenchMark AutoStainer, Ventana Medical
Systems, Tucson, AZ, USA) and the following primary anti-
bodies: CHGA rabbit polyclonal antiserum (diluted 1:1,200,
Dako GmbH, Hamburg, Germany), prediluted CHGA mono-
clonal antibody (Clone LK2H10, Roche), VGF rabbit poly-
clonal antiserum (diluted 1:1,000, Abcam, Cambridge, UK)
and prediluted SYP rabbit monoclonal antibody (Clone SP1,
Roche). Positive and negative controls (omission of the pri-
mary antibody and IgG-matched serum, pheochromocytoma
sections) were included for each immunohistochemical run.
Western Blot Analysis
Western blot (WB) analysis was performed on selected spec-
imens (fresh-frozen samples of two cases of pheochromocy-
toma of the adrenal gland, one case of NE carcinoma of the
breast, two cases of breast IC-NST) and on Jurkat lymphoid
cells to check the specificity of the antibody used and of the
immunohistochemical reaction.
For VGF expression analysis byWB, fresh-frozen samples
and Jurkat lymphoid cells were lysed at 4 °C for 1 h in a lysis
buffer (50 mm Tris–HCl, pH 8.3, containing 1 % Triton X-
100, 1 mm phenylmethylsulfonyl fluoride, 10 μm/ml
leupeptin and 100 units/ml aprotinin). After centrifugation of
the lysates at 15,000×g , protein contents of the supernatants
were measured using the Bradford method. Aliquots contain-
ing 30–50 μg of protein per lane were subjected to 10% SDS-
PAGE under reducing conditions and electroblotted onto ni-
trocellulose membrane filters. The blots were blocked with
5 % non-fat milk in 20 mM Tris–HCl, pH 7.5, 500 mM NaCl
plus 0.1 % Tween (TBS-T). The membranes were subsequent-
ly incubated overnight at 4 °C with polyclonal rabbit anti-
VGF antibody (Abcam, Cambridge, UK) at a concentration of
500 ng/ml. After extensive washing with TBS-T, the blots
were incubated for 1 h at room temperature with peroxidase-
conjugated protein A (200 ng/ml; Amersham Biosciences),
washed with TBS-T, developed with ECL detection reagents
(Amersham Biosciences) for 1 min and exposed to X-Omat
film (Eastman Kodak Co.).
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RNA Extraction
RNAwas extracted from both cytological FNAB samples and
frozen histological specimens. RNA extraction from cytolog-
ical specimens was carried out as previously reported [14]. For
frozen histological specimens, we proceeded as follows: the
suitability of the material was evaluated by haematoxylin and
eosin (H&E) staining; to obtain enough RNA for reverse
transcription-PCR, 15 to 20 cryosections were collected from
the OCT™ Tissue frozen blocks (20 μm thick) from each
specimen. The cryosections were collected into 1 ml of TRI
Reagent® solution (Ambion, Inc., Austin, TX) in a 1.5-ml
sterile Eppendorf tube and RNA extraction was performed
according to the manufacturer’s instructions.
RNA from FFPE tissues was extracted as previously de-
scribed [16]. RNA pellets were resuspended in DEPC-treated
water and quantified by spectrophotometry using a NanoDrop
1000 (Thermo Scientific, Waltham, MA, USA). Finally, RNA
samples were stored at −80 °C until further analysis.
Reverse Transcription
To remove any trace of DNA contamination, 1 μg of RNA
from each sample was treated with DNase I (1U/μl; Roche
Diagnostics, Mannheim, Germany). To obtain complementa-
ry DNA (cDNA), we used the high-capacity reverse transcrip-
tion kit (Applied Biosystems, Foster City, CA, USA) in a
reaction mixture with the following components: 1× reaction
buffer, 4 mM dNTPs, 1× random hexamers, 0.5 U/μl RNAse
inhibitor, 1.25 U/μl MultiScribe Reverse Transcriptase and
DEPC-Treated water. The reaction mixture was incubated at
25 °C for 10 min, at 37 °C for 2 h and finally at 85 °C for
5 min. RNA samples without reverse transcriptase were re-
verse transcribed and used as negative controls for DNA
contamination in PCR analysis. Reverse transcription prod-
ucts (cDNAs) were stored at −20 °C.
PCR Procedure for CHGA, SYP and VGF
The cDNA samples were amplified to assess chromogranin A
(CHGA—N M_001275.3), synaptophysin (SYP—
NM_003179.2) and neurosecretory protein VGF precursor
(VGF—NM_003378.3) gene expression, using the
touchdown-PCR conditions first reported by Korbie and
Mattick [17]. CHGA, SYP and VGF PCRwere independently
performed in a 50-μl reaction volume using the following
components: PCR reaction buffer (1× final), MgCl2
(1.5 mM final), dNTPs mix (200 μM final), primers (each
0.5 μM final), Taq DNA polymerase (1.25 U final) and
distilled water (dH2O). Primers, designed using the Oligo
explorer 1.5 Software, spanned two different exons resulting
in a target sequence of 272 bp for CHGA (primer sequences:
Fw. 5′-GCTCCAAGACCTCGCTCTCC-3′Rev. 5′-CCTGAT
TGTTCCCCTCAGCCT-3′), 349 bp for SYP (primer se-
quences: Fw. 5′-GTGCTGCAATGGGTCTTCG-3′ Rev. 5′-
CCGTGGCCAGAAAGTCCAG-3′) and 393 bp for VGF
(bases 184 to 576; primer sequences: Fw. 5′-TCGTGACA
CCAGCTGTCTCC-3′ Rev. 5′-GCACGGTCTCGGTCAG
CAGA-3′). The reactions were performed on a PTC-100
Peltier Thermal Cycler (MJ Research, Inc., MA, USA) and
PCR products were separated by electrophoresis on a 2 %
agarose gel-stained with ethidium bromide. To reduce the risk
of contamination from previously amplified products, sepa-
rate lab areas and equipment were used for RNA isolation,
amplification and electrophoresis.
Real-Time Quantitative PCR
We tested the recently described real-time quantitative PCR
(RTq-PCR) approach [16] using customized arrays with 24-
wells plates devised for investigating expression on NE
markers, comprehensive of CHGA and SYP. In three cases
on NE carcinomas (cases 1–3), RNA extracted from both,
fresh frozen and FFPE material was employed as described
[16]. RNA extracted from FFPE material was pre-amplified
following the suggested procedure.
Gene Arrays
Microarray gene expression profiling analysis was performed
using RNA extracted from FNAB leftover material available
for 24 of the 28 cases [14]. Briefly, biotinylated cRNA was
prepared using the Illumina TotalPrep RNAAmplification Kit
(Ambion, Inc., Austin, TX) beginning with 500 ng of total
RNA and following the manufacturer’s recommendations.
Hybridization of the cRNA to the HumanHT-12_V4 Expres-
sion BeadChip (Illumina, Inc., San Diego, CA), washing and
scanning were performed according to the Illumina
BeadStation 5006 manual (revision C). Microarray data were
summarized and cubic-spline normalized with the
GenomeStudio software (Illumina Inc., San Diego, USA)
and subsequently analysed using Excel (Microsoft). The en-
tire microarray dataset is MIAME compliant. Raw and nor-
malized expression data are deposited in Gene Expression
Omnibus (GEO Accession number GSE27175). Log(2) trans-
formed expression data were extracted for the genes of interest
and then employed, together with detection p values, for
visualization or for definition of sample positivity.
Meta-analysis of Published Gene Expression Data
To validate our results in a large cohort of breast cancer
patients, we focused on a published gene expression dataset
obtained using Affymetrix DNA microarrays on 103 biopsies
of aggressive breast carcinomas that were subjected to neoad-
juvant treatment [18]. Gene expression data were downloaded
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from Gene Expression Omnibus (GEO ID: GSE22093) and
analysed with Microsoft Excel.
Results
Expression of CHGA and SYP
The four cases of NE carcinomas of the breast (cases 1–4)
showed IHC positivity in >50 % of neoplastic cells for SYP
(all cases) and CHGA (cases 1, 2 and 4, but not case 3 which
was negative). Moreover, scattered neoplastic cells were
found positive for CHGA in cases 5 and 28 (Fig. 1) while
for SYP in cases 8 and 26.
A high level of gene expression for CHGA and SYP was
detected in all IHC-positive cases, irrespective of the number
of positive cells. Significant discrepancies in the expression of
these two markers were observed in five cases (N. 3, 8, 20, 26,
28; Figs. 2 and 3).
Concordant results were obtained with PCR and gene array
procedures. Using the RTq-PCR procedure in three cases on
NE carcinoma (Fig. 4), similar and compatible results were
obtained by either scatter plot or average delta Ct analysis,
using RNA extracted from fresh frozen and from archival
material, thus proving the validity of FFPE material for de-
tecting NE gene expression. In case 3, which was negative for
CHGA in IHC, gene expression for this NE marker was 35,
000-fold down-regulated as compared to cases 1 and 2
(Table 1).
Expression of VGF
VGF distribution, as detected by IHC, resulted in a rather
weak and diffuse staining in the four cases of NE
Fig. 1 IHC for VGF. a A NE
breast cancer (case 2) shows IHC
expression of VGF of variable
intensity in the vast majority of
cancer cells. b VGF positivity in
an invasive carcinoma, no special
type (IC-NST) breast cancer (case
5) displaying solid histological
patterns. c The in situ (right) and
invasive glandular component in
case 10 have different positivity
for VGF, which is more intense in
the former. d
Immunohistochemical staining
for chromogranin A shows
scattered positive cells. The
tumour (case 28) showed gene
expression positivity for the same
NE marker (×100, nuclei
counterstained with Haemalum)
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carcinomas (Fig. 1b). An apparently non-specific staining
was detected in some cells in normal ducts, which might
suggest a poor specificity of the available antibody. Since
the immunohistochemical approach on FFPE tissue section
proved poorly reliable, we used WB analysis to confirm the
production of the immuno-reactive VGF protein of the pre-
dicted MW of 67 kDa in case 1 of NE carcinoma (Fig. 5) as
well as in two additional cases which proved positive for VGF
gene expression (see below). In the NE carcinoma, a weaker
but definite additional band was detected at a higher MW
(approximately 80 kDa).
VGF gene expression by RT-PCR and gene array analysis
was found in all four NE breast carcinomas that were CHGA
and/or SYP positive at the mRNA and protein level (Table 1).
The analysis of two non-neoplastic breast specimens gave
negative results, whereas two cases of pheochromocytoma
expressed by RT-PCR high levels of mRNA for both CHGA
and VGF, confirming VGF as a marker of NE differentiation
(Fig. 2). Surprisingly, in addition to the four NE carcinomas,
VGF was expressed at high level in eight breast carcinomas
negative for CHGA and/or SYP (cases 5, 6, 7, 8, 9, 10, 11
and12) and at moderate level in cases 13, 14 and 15 (Figs. 2
and 3). The gene expression profile of these eight cases is
strongly positive for VGF (detection p <0.01 and Log(2)
signal > 9) when matched with published expression-based
classifiers [19] fit with the basal tumour type signature
(Fig. 3). Of these, six cases were G3 and two were G2
(Table 1).
The relative expression of CHGA, SYP and VGF is report-
ed in Fig. 3 which shows variation of expression level of the
three NE markers in different breast cancers.
Meta-analysis of NE Markers Expression in Publicly
Available Datasets of Breast Carcinomas
To check the reproducibility of the observed results, we
focused on a published gene expression dataset of 103
breast cancer biopsies originally reported by Iwamoto
and colleagues [18]. We evaluated the distribution of
CHGA, SYP and VFG expression and found that all
Fig. 2 RT-PCR for
chromogranin-a (CHGA) and
VGF in NE (cases 1 and 4) and
non-NE samples (cases 8, 9, 15,
16 and 26). Two cases of
pheochromocytoma of the
adrenal gland were used as
positive controls
Fig. 3 In the waterfall plot, the 24 samples are sorted from left to right
according to decreasing levels of VGF mRNA (light blue columns, left y-
axis scale). For each sample, the coloured squares represent one of the
three transcriptional scores (right y-axis scale): luminal a (green), luminal
b (dark green) and basal (red). Blue and dark blue columns represent
SYP and CHGA, respectively. Except for the sample expressing the
highest VGF levels, carrying a luminal B profile, samples displaying
high levels of VGF (above a log2 signal of 9) have a basal-like profile
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three genes have variable expression levels. For each
gene, it is possible to define a threshold above which
expression can be considered high (Fig. 6). Out of the
103 samples analysed, the Log2 signal is, respectively
higher than nine for CHGA in ten samples, higher than
eight for SYP in 12 samples and higher than nine in
VGF for ten samples. A paired comparison of expres-
sion for the three genes displayed an overall correlation,
especially between SYP and VGF expression (Fig. 7a–
c). Finally, we analysed how many cases had high
expression is in two or more genes in the same sample.
Interestingly, while there is only one sample with high
expression of all three genes, eight of the ten VGF-high
samples also had high expression of CHGA or SYP
(Fig. 7d). We finally compared expression of the three neu-
roendocrine marker genes with estrogen receptor and ERBB2
expression, measured at the RNA level by the same microar-
ray experiment. The three genes displayed a concordant be-
haviour, being expressed at high level preferentially, though
not exclusively, in estrogen receptor-positive, ERBB2-
negative samples (Supplementary Figures 1 and 2).
Fig. 4 Plot of the average delta Ct matching by `q-PCR, in three cases of
NE carcinomas of the breast (cases 1, 2 and 3), the RNA extracted from
fresh frozen and FFPE material. The results, confirmed also by scatter
plot analysis, show the suitability of FFPE samples for the assessment of
CHGA and SYP gene expression
Table 1 Histopathological and
molecular features of the study
cohort
CHGA chromogranin A, ER es-
trogen receptor, G histological
grade, IC-NST invasive carcino-





Case no. Histological type G Gene expression IHC
CHGA SYP VGF ER HER2 Ki67
1 NE 2 +++ +++ +++ 100 0 16
2 Mucinous NE 1 ++ +++ + 100 1 2
3 NE 3 − +++ ++ 0 0 35
4 NE 2 +++ ++ +++ 100 0 23
5 IC+mucinous 3 ++ − ++ 70 3 35
6 IC-NST 3 − − ++ 0 0 43
7 IC-NST 2 − − ++ 4 0 60
8 IC-NST 3 − + ++ 0 0 70
9 IC-NST 3 − − ++ 0 0 70
10 IC-NST 2 − − ++ 5 1 17
11 IC-NST 3 − − ++ 0 3 43
12 IC-NST 3 − − ++ 95 3 16
13 IC-NST 2 − − + 0 0 44
14 Medullary 3 − − + 0 0 25
15 IC-NST 3 − − + 1 0 60
16 Intracystic papillary 1 − − − 100 0 20
17 IC-NST 2 − − − 95 1 28
18 IC-NST 2 − − − 95 0 21
19 IC-NST 1 − − − 90 1 28
20 IC-NST 2 − + − 100 1 14
21 Intracystic papillary 1 − − − 100 1 18
22 IC-NST 2 − − − 100 0 9
23 IC-NST 2 − − − 95 1 30
24 Tubular 1 − − − 95 1 19
25 ILC 2 − − − 88 0 11
26 IC-NST 2 − + − 95 1 6
27 IC-NST 3 − − − 65 3 34
28 IC-NST 3 +++ − − 95 3 25
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Discussion
The present study is, to our knowledge, the first integrated
approach to the definition of NE carcinomas of the breast
using IHC and gene expression analysis of specific NE
markers. In the four cases (cases 1–4) falling into the proper
2003 WHO definition of NE carcinomas of the breast [3] and
showing CHGA and/or SYP protein expression in the major-
ity of cancer cells, gene expression analysis matched the IHC
data, thus confirming by an alternative procedure, the exis-
tence of a subset of carcinomas of the breast fully oriented
towards NE differentiation. In the other 24 cases, a strong
expression of at least one NE gene corresponded to a focal
positivity or negativity of the related protein. This might be
attributed either to a higher sensitivity of the genetic analysis
or, less likely, to failure of transduction. The results obtained
in our limited series of 28 cases were confirmed by a paired
comparison of expression for the CHGA, SYP and VGF
genes performed in a publicly available dataset of 103 aggres-
sive breast carcinomas [18] where 10 % of cases showed gene
Fig. 5 Western blot for VGF. VGF expression analysis by WB per-
formed on two cases of breast IC-NST (cases 5 and 6), one case of NE
carcinoma (case 1) of the breast and two cases of pheochromocytoma of
the adrenal gland (positive control) and on Jurkat lymphoid cells (nega-
tive control)
Fig. 6 Expression of CHGA,
SYP and VGF in 103 breast
cancer samples. Waterfall plots
showing the expression levels of
a CHGA, b SYP and c VGF in
103 breast cancer biopsies. In
each panel the samples are sorted
by descending levels of the
respective gene analysed. The red
lines indicate the threshold above
which samples are considered to
express high levels of the gene
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overexpression of at least one NE marker (detection p <0.01
and Log(2) signal> 9) and showed that there is only a partial
correlation among these three markers, CHGA expression
being often unrelated with that of SYP and VGF.
A significant fraction of breast cancers is characterized by a
solid or trabecular arrangement of cells, which may also form
pseudo-rosettes and, as remarked by Eusebi and Tavassoli
[20], are histologically strongly reminiscent of NE tumours
of the gastro-intestinal tract. However, only a minority (ap-
proximately 2 %) of cancers can properly be defined as NE
carcinomas of the breast as reported in the 2003 WHO “blue”
book [3]. In the literature, the incidence of IBC showing
evidence of NE differentiation shows ample variation depend-
ing on the criteria and detection methods [1–3].
NE differentiation in IBC has so far been achieved through
the IHC detection of “general” NE markers, i.e., CHGA and
SYP [4, 21–23]. Despite its definite advantages and merits,
the IHC approach suffers drawbacks linked to the specificity
of the antibodies and to the efficacy of the antigen retrieval
procedures. Moreover, the specificity of SYP as an IHC NE
marker, despite being improved by the use of high-affinity
rabbit monoclonal antibodies, is not absolute, given the re-
ported positivity in adreno-cortical neoplasms [24]. CHGA
and SYP are regarded as markers of NE differentiation struc-
turally linked to cytoplasmic granules and vesicles and are, as
a rule, simultaneously expressed in typical NETs of different
organs such as pheocromocytomas, intestinal and lung carci-
noids and pancreatic NETs [8, 25].
In breast cancers, as remarked in the present study, IHC
positivity for NE markers is often limited to a single marker
and/or to a minority of cancer cells. It might well be argued
that this phenomenon might either be related to poor storage
Fig. 7 Analysis of correlation between CHGA, SYP and VGF expres-
sion in 103 breast cancer samples. Dot plots comparing expression (log2
Signal) of a CHGAvs SYP, b CHGAvs VGF and c SYP vs VGF in 103
breast cancer biopsies. Red straight lines indicate the thresholds above
which samples are considered to express high gene levels. Red dotted
lines define samples with high expression of both genes in the panel. d
Venn Diagram indicating coexpression of high levels of CHGA, SYP and
VGF
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of the markers or to a low sensitivity of the procedure. In order
to elucidate the issue, we have conducted an integrated ap-
proach, using both IHC and gene expression profiling for
three “general” NE markers. Although RT-PCR and gene
array procedures require the use of RNA extracted from fresh
frozen samples, in the present study, we confirmed that the
RTq-PCR procedure can reliably be performed on RNA ob-
tained from archival FFPE tissue blocks. This novel approach
could complement IHC in the definition of NE differentiation
in breast cancers as we have already demonstrated in pancre-
atic neoplasms [16].
As an additional result, we demonstrated that VGF a re-
cently described NE marker showing similarities with mem-
bers of the secretogranin/chromogranin family [11] is also
expressed in NE breast cancers producing CHGA and/or
SYP. In addition, expression of VGF gene was detected in a
significant number (10 %) of breast cancers in a large series of
aggressive breast carcinomas from a published series [18].
Evidence that VGF gene is over-expressed in a significant
number of primary breast cancers was obtained by both PCR
and gene array procedures. This is apparently in contrast with
the study by Ostrow et al. [26] showing that VGF gene was
methylated (thus probably silenced) in a vast number of breast
cancer cell lines and not in normal tissues.
Finally, discordant data have been reported on the clinical
evolution of NEC probably depending on the definition
criteria of the case series. According to Wei et al. [27], these
tumours represent an aggressive variant, while others maintain
that their behaviour does not vary from that of invasive
carcinoma NST in relation to grade, stage and expression of
estrogen and progesterone receptors (ER and PgR) [2, 4, 6]. In
addition, while genetic analyses specifically focused on NE
breast tumours allowed to include them among the “Luminal
A” or, less frequently, the “Luminal B” subgroup [28], the
gene expression profile of most VGF-positive breast cancer
classified them as basal. The potential diagnostic and clinical
interest of these findings demands further investigations in
large cohorts with correlation with clinical outcome.
In conclusion, the gene expression of one or more markers
on NE differentiation in invasive breast cancers, as demon-
strated in the present study, seems a relatively frequent occur-
rence whose clinical and biologic significance is presently
unknown. The adoption of specifically designed sets of cus-
tomized arrays could allow the evaluation of expression of
genes related to NE differentiation, to tumour aggressiveness
and to factors predictive of response to treatment, thus open-
ing the way to selectively tailored treatments.
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